These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 11181370

  • 21. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
    Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R.
    Antimicrob Agents Chemother; 2009 Feb; 53(2):428-34. PubMed ID: 19015332
    [Abstract] [Full Text] [Related]

  • 22. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.
    Dandekar PK, Tessier PR, Williams P, Zhang C, Nightingale CH, Nicolau DP.
    Chemotherapy; 2004 Apr; 50(1):11-6. PubMed ID: 15084799
    [Abstract] [Full Text] [Related]

  • 23. In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.
    Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6568-74. PubMed ID: 26259789
    [Abstract] [Full Text] [Related]

  • 24. Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection.
    Wang J, Shan Q, Ding H, Liang C, Zeng Z.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3008-12. PubMed ID: 24614373
    [Abstract] [Full Text] [Related]

  • 25. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
    Craig WA, Andes DR.
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [Abstract] [Full Text] [Related]

  • 28. Daptomycin dose-effect relationship against resistant gram-positive organisms.
    Cha R, Grucz RG, Rybak MJ.
    Antimicrob Agents Chemother; 2003 May; 47(5):1598-603. PubMed ID: 12709328
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy.
    De Gregori S, De Silvestri A, Molinaro MD, Monzillo V, Biscarini S, Colaneri M, Gallazzi I, Bartoli A, Bruno R, Seminari E.
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.
    Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J.
    Int J Antimicrob Agents; 2013 Jul; 42(1):53-8. PubMed ID: 23684388
    [Abstract] [Full Text] [Related]

  • 32. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
    Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
    [Abstract] [Full Text] [Related]

  • 33. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
    Lepak A, Marchillo K, VanHecker J, Andes D.
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
    [Abstract] [Full Text] [Related]

  • 34. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [Abstract] [Full Text] [Related]

  • 37. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation.
    Olney KB, Howard JI, Burgess DS.
    J Clin Pharmacol; 2024 Jul; 64(7):860-865. PubMed ID: 38497326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.